• Publications
  • Influence
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires
TLDR
Differences in the responses to the items in the brain cancer module appear to reflect differences in neurological status, as deteriorating neurological status was accompanied by a marked increase in emotional distress, future uncertainty and motor dysfunction.
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
TLDR
In the extended Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozolmide, which is easy to use clinically and generally well tolerated.
Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin
TLDR
CHM and healthy co-twin pregnancies have a high risk of spontaneous abortion, but about 40% result in livebirths, without significantly increasing the risk of pGTD.
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
TLDR
EMA/CO is an effective and well-tolerated regimen for high-risk GTT and more than half of the women will retain their fertility; however, there is a small but significant risk of second malignancy.
Defining and measuring reproductive concerns of female cancer survivors.
TLDR
The preliminary data suggest that at least for vulnerable subgroups, the issue of reproductive concerns is worthy of additional investigation to assist cancer survivors living with the threat or reality of infertility.
HISTOPATHOLOGY IN THE PREDICTION OF RELAPSE OF PATIENTS WITH STAGE I TESTICULAR TERATOMA TREATED BY ORCHIDECTOMY ALONE
TLDR
259 patients with stage I non-seminomatous germ-cell testicular teratoma treated by orchidectomy alone and monitored at one often centres in the United Kingdom were followed for a median of 30 months, with a 2-year relapse-free rate of 74%, falling to 68% at 4 years.
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.
TLDR
This is the first study to identify stage and tumor markers as prognostic parameters for patients with MOGCTs and to select patients for risk-adapted treatment, and there is need for improvement of therapeutic strategies after relapse.
Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine
TLDR
EP/EMA is an effective but moderately toxic regimen for patients with high-risk GTT who become refractory to or relapse from EMA/CO chemotherapy and clearly has activity in patients with metastatic PSTT.
...
1
2
3
4
5
...